drugset / Trial / NCT05691829
Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test if low dose radiation, which is routinely used in treating patients with lung cancer for symptom control, can improve the results from the standard treatment with pembrolizumab and chemotherapy. In this study, only individuals who have NSCLC that is advanced (Stage IV), or has come back (recurred), will be able to participate.
Timeline
- Start
- 2023-01-24
- Primary completion
- 2024-06-20
- Completion
- 2025-04-21
Outcome
Outcome not reported
Stopped (Enrollment): “Terminated due to insufficient enrollment.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Carboplatin | Small molecule | — | — |
| Background | Nab-paclitaxel | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Pemetrexed | Small molecule | — | — |